NASDAQ:DXCM DexCom (DXCM) Stock Price, News & Analysis $64.00 -43.85 (-40.66%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$62.34▼$67.4450-Day Range$64.00▼$130.8452-Week Range$62.34▼$142.00Volume53.84 million shsAverage Volume3.28 million shsMarket Capitalization$25.45 billionP/E Ratio41.29Dividend YieldN/APrice Target$139.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get DexCom alerts: Email Address DexCom MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.87 Rating ScoreUpside/Downside76.7% Upside$113.06 Price TargetShort InterestHealthy2.62% of Shares Sold ShortDividend StrengthN/ASustainability-0.76Upright™ Environmental ScoreNews Sentiment0.42Based on 54 Articles This WeekInsider TradingSelling Shares$480,861 Sold Last QuarterProj. Earnings Growth24.72%From $1.78 to $2.22 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.98 out of 5 starsMedical Sector4th out of 936 stocksSurgical & Medical Instruments Industry4th out of 101 stocks 4.4 Analyst's Opinion Consensus RatingDexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 11 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageDexCom has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about DexCom's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.62% of the outstanding shares of DexCom have been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently increased by 1.07%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDexCom has received a 75.05% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Continuous glucose monitoring systems" and "Blood glucose monitors" products. See details.Environmental SustainabilityThe Environmental Impact score for DexCom is -0.76. Previous Next 3.0 News and Social Media Coverage News SentimentDexCom has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 54 news articles for DexCom this week, compared to 13 articles on an average week.Search Interest40 people have searched for DXCM on MarketBeat in the last 30 days. This is an increase of 135% compared to the previous 30 days.MarketBeat Follows14 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $480,861.00 in company stock.Percentage Held by InsidersOnly 0.30% of the stock of DexCom is held by insiders.Percentage Held by Institutions97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DexCom's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for DexCom are expected to grow by 24.72% in the coming year, from $1.78 to $2.22 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 41.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.35.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 41.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 156.32.Price to Earnings Growth RatioDexCom has a PEG Ratio of 2.74. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDexCom has a P/B Ratio of 11.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DexCom's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here About DexCom Stock (NASDAQ:DXCM)DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Read More DXCM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DXCM Stock News HeadlinesJuly 11, 2024 | marketbeat.comTop 4 Must-Have Healthcare Stocks for Long-Term GrowthThe healthcare industry represents a substantial and dynamic market sector, presenting many opportunities for investors seeking long-term growth and stability. Factors such as the aging population, technological advances, and rising healthcare costs provide the sector with a compelling combination of growth potential and resilience.July 11, 2024 | marketbeat.comTop 4 Must-Have Healthcare Stocks for Long-Term Growth (DXCM)Investing in healthcare offers long-term growth and stability fueled by demographic trends, technological advancements, and rising demand.July 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.June 29, 2024 | insidertrades.comInsider Selling: DexCom, Inc. (NASDAQ:DXCM) EVP Sells 659 Shares of StockJuly 26 at 9:00 PM | globenewswire.comDEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of DexCom Stockholders and Encourages Investors to Contact the FirmJuly 26 at 7:16 PM | msn.comDexcom Stock Crashes 41% After Slashing Its Guidance On A 'Painfully Self-Inflicted' QuarterJuly 26 at 3:15 PM | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of DexCom, Inc. (DXCM) on Behalf of InvestorsJuly 26 at 11:00 AM | proactiveinvestors.comDexCom slashes full-year sales forecast, shares plummetJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! July 26 at 10:42 AM | fool.comWhy DexCom Stock Is Crashing TodayJuly 26 at 9:17 AM | globenewswire.comDXCM INVESTIGATION ALERT: BFA Law Announces that it is Investigating DexCom, Inc. (NASDAQ:DXCM) for Securities Fraud; Investors who Suffered Losses are Encouraged to Contact the FirmJuly 26 at 8:49 AM | barrons.comDexCom Stock Plunges 37% After Earnings. GLP-1s Weren't the Problem.July 26 at 8:33 AM | globenewswire.comJohnson Fistel Begins Investigation into DexCom Following a Significant Drop in the Company's StockJuly 26 at 8:29 AM | investorplace.comWhy Is DexCom (DXCM) Stock Down 38% Today?July 26 at 6:15 AM | investorplace.comGet Your Money Out of These 3 Nasdaq Stocks by the End of JulyJuly 26 at 5:23 AM | reuters.comDexcom plunges 40% after glucose monitor maker slashes sales forecastJuly 26 at 3:04 AM | seekingalpha.comDexCom Q2: Surprising Earnings Miss With Hints Of Competitive PressuresJuly 26 at 12:17 AM | finance.yahoo.comDexCom (DXCM) Q2 2024 Earnings Call TranscriptSee More Headlines Receive DXCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/25/2024Today7/26/2024Next Earnings (Estimated)10/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:DXCM CUSIP25213110 CIK1093557 Webwww.dexcom.com Phone(858) 200-0200Fax858-200-0201Employees9,600Year Founded1999Price Target and Rating Average Stock Price Target$115.60 High Stock Price Target$161.00 Low Stock Price Target$75.00 Potential Upside/Downside+119.5%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)$1.55 Trailing P/E Ratio40.95 Forward P/E Ratio35.66 P/E Growth2.74Net Income$541.50 million Net Margins16.82% Pretax Margin20.48% Return on Equity31.01% Return on Assets10.29% Debt Debt-to-Equity Ratio1.08 Current Ratio2.90 Quick Ratio2.53 Sales & Book Value Annual Sales$3.62 billion Price / Sales6.97 Cash Flow$1.17 per share Price / Cash Flow54.10 Book Value$5.35 per share Price / Book11.86Miscellaneous Outstanding Shares397,680,000Free Float396,491,000Market Cap$25.24 billion OptionableOptionable Beta1.16 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Kevin Ronald Sayer (Age 66)Executive Chairman, CEO & President Comp: $3.23MMr. Jereme M. Sylvain (Age 44)Executive VP, CFO & Chief Accounting Officer Comp: $1.13MMr. Jacob Steven Leach (Age 46)Executive VP & COO Comp: $1.29MMr. Michael Jon Brown (Age 54)Executive VP & Chief Legal Officer Comp: $1.22MMs. Teri Lawver (Age 57)Executive VP & Chief Commercial Officer Comp: $1.41MMr. Girish Naganathan (Age 47)Executive VP & CTO Comp: $423.92kMr. Shelly Ramasamy Selvaraj (Age 65)Senior VP & Chief Information Officer Mr. Sean ChristensenDirector of Corporate Affairs & Head of Investor RelationsMr. Matthew Dolan (Age 43)Executive Vice President of Strategy, Corporate Development & Dexcom Labs Ms. Leverne MarshExecutive Vice President of MarketingMore ExecutivesKey CompetitorsAbiomedNASDAQ:ABMDNovoCureNASDAQ:NVCRAbbott LaboratoriesNYSE:ABTIntuitive SurgicalNASDAQ:ISRGStrykerNYSE:SYKView All CompetitorsInsiders & InstitutionsEFG Asset Management North America Corp.Sold 2,595 shares on 7/26/2024Ownership: 0.008%WealthShield Partners LLCBought 1,346 shares on 7/26/2024Ownership: 0.004%Patriot Financial Group Insurance Agency LLCBought 483 shares on 7/26/2024Ownership: 0.003%Mitsubishi UFJ Asset Management UK Ltd.Bought 2,000 shares on 7/26/2024Ownership: 0.001%SlateStone Wealth LLCBought 521 shares on 7/26/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions Should I Buy DexCom Stock? DXCM Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in DexCom, Inc.: DexCom's recent positive earnings report, beating the consensus estimate by $0.05 per share, indicates strong financial performance. The company's focus on continuous glucose monitoring (CGM) systems for diabetes management aligns with the growing demand for healthcare technology solutions. With a consensus target price of $140.94, there is potential for stock price appreciation, making it an attractive investment opportunity. DexCom's consistent revenue growth, with $921.00 million reported in the last quarter, demonstrates a healthy financial outlook. The company's strong return on equity of 31.01% showcases efficient utilization of shareholder funds for profitability. Cons Investors should be bearish about investing in DexCom, Inc. for these reasons: The stock's price-to-earnings ratio of 75.61 may indicate an overvalued position, potentially leading to limited upside for investors. Despite positive ratings from analysts, the stock's beta of 1.22 suggests higher volatility compared to the market average, posing risk for investors. Insider selling activity, with company insiders offloading significant shares in recent months, could signal lack of confidence in future growth prospects. The company's debt-to-equity ratio of 1.08 raises concerns about its leverage position and ability to manage debt obligations effectively. While revenue growth has been strong, the price-to-earnings-growth ratio of 2.85 may indicate that the stock is not undervalued based on its growth prospects. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, July 5, 2024. Please send any questions or comments about these DexCom pros and cons to contact@marketbeat.com. DXCM Stock Analysis - Frequently Asked Questions How have DXCM shares performed this year? DexCom's stock was trading at $124.09 at the beginning of the year. Since then, DXCM shares have decreased by 48.4% and is now trading at $64.00. View the best growth stocks for 2024 here. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) released its earnings results on Thursday, July, 25th. The medical device company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.04. DexCom's quarterly revenue was up 15.3% compared to the same quarter last year. When did DexCom's stock split? DexCom shares split on the morning of Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly minted shares were payable to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. What is Kevin Sayer's approval rating as DexCom's CEO? 347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees. Does DexCom have any subsidiaries? DexCom subsidiaries include these companies: TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and more. Who are DexCom's major shareholders? DexCom's top institutional investors include Baillie Gifford & Co. (3.85%), Vaughan Nelson Investment Management L.P. (0.41%), Allspring Global Investments Holdings LLC (0.26%) and Sumitomo Mitsui Trust Holdings Inc. (0.22%). Insiders that own company stock include Kevin R Sayer, Jacob Steven Leach, Steven Robert Pacelli, Jereme M Sylvain, Sadie Stern, Michael Jon Brown, Barry J Regan, Steven R Altman, Paul R Flynn, Shelly Ramasamy Selvaraj, Matthew Vincent Dolan, Bridgette P Heller, Chad Patterson, Andrew K Balo, Barbara Kahn, Richard Alexander Collins, Mark G Foletta, Patrick Michael Murphy and Nicholas Augustinos. View institutional ownership trends. How do I buy shares of DexCom? Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM) and ServiceNow (NOW). This page (NASDAQ:DXCM) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DexCom With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
